GlaxoSmithKline reports phase III success for bepirovirsen in chronic hepatitis B
Source: SeekingAlpha
2026-01-07 05:46:16 ET
More on GSK
- GSK: 2026 Looks Good
- GSK: Depemokimab And Jemperli Lead Next Wave (Rating Upgrade)
- GSK plc (GSK) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
- GlaxoSmithKline says Exdensur approved in Japan for severe asthma and CRSwNP
- CDC updates childhood vaccine schedule to recommend fewer shots
Read the full article on Seeking Alpha
For further details see:
GlaxoSmithKline reports phase III success for bepirovirsen in chronic hepatitis B
Academy Sports and Outdoors Inc.
NASDAQ: ASO
ASO Trading
3.86% G/L:
$60.835 Last:
510,186 Volume:
$58.44 Open:
ASO Latest News
March 10, 2026 09:05:00 am
Academy Sports + Outdoors Grows Retail Footprint with Two New Locations in Ohio and Oklahoma
ASO Stock Data
$3,822,172,116
64,267,437
0.73%
142
N/A
Retail - Discretionary
Consumer Discretionary
US
Katy
